Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love DexCom (DXCM)
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DXCM continues to raise investor optimism due to its strong product portfolio.
Top Health & Fitness Stocks to Buy for the Wellness Boom
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
5 Best Stocks of the S&P 500 ETF in the Past Month
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establishing a reaccelerating trend in growth for the company. However, DXCM's competitor product, Abbott's Libre Freestyle, has been growing faster despite larger sales.
